FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885442085> ?p ?o ?g. }

• W2885442085 abstract "In the last five years, the treatment of advanced melanoma has been revolutionised by the introduction of selective kinase inhibitors and immunotherapy. Selective inhibition of the mitogen activated protein kinase (MAPK) pathway has significantly improved the survival of patients with BRAFV600-mutant melanoma, and combination MEK and CDK4 inhibition is currently being trialed in patients with NRAS-mutant melanoma. Almost a quarter of all melanomas, however, are wild type for BRAF and NRAS and have no known actionable mutations. Currently, patients with wild type melanoma are treated with immunotherapies, which produce prolonged responses, but only in a small subset of patients. Overall, the prognosis for patients with wild type melanomas remains poor, and there is an urgent need to establish better therapeutic strategies for these patients. In order to define new therapeutic targets in BRAF/NRAS wild type melanoma, we sought to characterize the key proliferative and survival pathways in wild type melanomas. Wild type (n=14) and BRAFV600 (n=7) melanomas were treated with the MEK inhibitor trametinib at increasing doses from 0.5nM to 5000nM for 72h and sensitivity to MEK inhibition was assessed using viability assays. Signaling pathway activity in response to trametinib (10nM, 24h) was also examined in our panel of melanoma cells using the Human Phospho-Kinase Antibody Array (RD 36%) were sensitive to trametinib (IC50 0.5-4.9nM), the majority of these melanoma cells (9/14; 64%) were resistant to trametinib (IC50 10.5-264.8nM). Analysis of kinase activation status revealed little difference in signaling pathway activity between the sensitive and resistant wild type melanomas at baseline. Resistant wild type melanomas had higher activity of STAT3 compared to the sensitive cell lines. However, all these wild type melanomas showed variable activation of multiple signaling pathways that were not active in BRAFV600 melanomas. Specifically, at baseline, wild type melanomas showed pronounced activation of the JNK and p38 MAPK pathways, the FAK/Src pathway (i.e. FAK, Lck, Lyn, Fgr and Yes), the epidermal growth factor receptor tyrosine kinase and β-catenin compared to BRAFV600 melanomas. Activation of multiple signaling pathways in wild type melanomas may contribute to innate resistance or limit the efficacy of MEK inhibition, and we are currently exploring the impact of these pathways on the survival and MEK dependence of wild type melanomas. Citation Format: Zizhen Ming, Su Yin Lim, Richard F. Kefford, Helen Rizos. Multiple signalling pathways are active in BRAF/NRAS wild type melanomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 765." @default.
• W2885442085 created "2018-08-22" @default.
• W2885442085 creator A5009857756 @default.
• W2885442085 creator A5055742600 @default.
• W2885442085 creator A5069277796 @default.
• W2885442085 creator A5078586769 @default.
• W2885442085 date "2018-07-01" @default.
• W2885442085 modified "2023-09-25" @default.
• W2885442085 title "Abstract 765: Multiple signalling pathways are active in BRAF/NRAS wild type melanomas" @default.
• W2885442085 doi "https://doi.org/10.1158/1538-7445.am2018-765" @default.
• W2885442085 hasPublicationYear "2018" @default.
• W2885442085 type Work @default.
• W2885442085 sameAs 2885442085 @default.
• W2885442085 citedByCount "0" @default.
• W2885442085 crossrefType "proceedings-article" @default.
• W2885442085 hasAuthorship W2885442085A5009857756 @default.
• W2885442085 hasAuthorship W2885442085A5055742600 @default.
• W2885442085 hasAuthorship W2885442085A5069277796 @default.
• W2885442085 hasAuthorship W2885442085A5078586769 @default.
• W2885442085 hasConcept C104317684 @default.
• W2885442085 hasConcept C121608353 @default.
• W2885442085 hasConcept C126322002 @default.
• W2885442085 hasConcept C143065580 @default.
• W2885442085 hasConcept C143998085 @default.
• W2885442085 hasConcept C184235292 @default.
• W2885442085 hasConcept C207583985 @default.
• W2885442085 hasConcept C21790070 @default.
• W2885442085 hasConcept C2776131300 @default.
• W2885442085 hasConcept C2777658100 @default.
• W2885442085 hasConcept C2778472372 @default.
• W2885442085 hasConcept C2778830669 @default.
• W2885442085 hasConcept C2781187634 @default.
• W2885442085 hasConcept C2781249067 @default.
• W2885442085 hasConcept C2994587330 @default.
• W2885442085 hasConcept C502942594 @default.
• W2885442085 hasConcept C526805850 @default.
• W2885442085 hasConcept C55493867 @default.
• W2885442085 hasConcept C57074206 @default.
• W2885442085 hasConcept C71924100 @default.
• W2885442085 hasConcept C86803240 @default.
• W2885442085 hasConcept C95444343 @default.
• W2885442085 hasConcept C97029542 @default.
• W2885442085 hasConceptScore W2885442085C104317684 @default.
• W2885442085 hasConceptScore W2885442085C121608353 @default.
• W2885442085 hasConceptScore W2885442085C126322002 @default.
• W2885442085 hasConceptScore W2885442085C143065580 @default.
• W2885442085 hasConceptScore W2885442085C143998085 @default.
• W2885442085 hasConceptScore W2885442085C184235292 @default.
• W2885442085 hasConceptScore W2885442085C207583985 @default.
• W2885442085 hasConceptScore W2885442085C21790070 @default.
• W2885442085 hasConceptScore W2885442085C2776131300 @default.
• W2885442085 hasConceptScore W2885442085C2777658100 @default.
• W2885442085 hasConceptScore W2885442085C2778472372 @default.
• W2885442085 hasConceptScore W2885442085C2778830669 @default.
• W2885442085 hasConceptScore W2885442085C2781187634 @default.
• W2885442085 hasConceptScore W2885442085C2781249067 @default.
• W2885442085 hasConceptScore W2885442085C2994587330 @default.
• W2885442085 hasConceptScore W2885442085C502942594 @default.
• W2885442085 hasConceptScore W2885442085C526805850 @default.
• W2885442085 hasConceptScore W2885442085C55493867 @default.
• W2885442085 hasConceptScore W2885442085C57074206 @default.
• W2885442085 hasConceptScore W2885442085C71924100 @default.
• W2885442085 hasConceptScore W2885442085C86803240 @default.
• W2885442085 hasConceptScore W2885442085C95444343 @default.
• W2885442085 hasConceptScore W2885442085C97029542 @default.
• W2885442085 hasLocation W28854420851 @default.
• W2885442085 hasOpenAccess W2885442085 @default.
• W2885442085 hasPrimaryLocation W28854420851 @default.
• W2885442085 hasRelatedWork W1510276410 @default.
• W2885442085 hasRelatedWork W1980427440 @default.
• W2885442085 hasRelatedWork W1984899592 @default.
• W2885442085 hasRelatedWork W2003360338 @default.
• W2885442085 hasRelatedWork W2105317859 @default.
• W2885442085 hasRelatedWork W2164992866 @default.
• W2885442085 hasRelatedWork W2571001524 @default.
• W2885442085 hasRelatedWork W2617846385 @default.
• W2885442085 hasRelatedWork W2767735945 @default.
• W2885442085 hasRelatedWork W2885442085 @default.
• W2885442085 isParatext "false" @default.
• W2885442085 isRetracted "false" @default.
• W2885442085 magId "2885442085" @default.
• W2885442085 workType "article" @default.